SARS-CoV2 Nucleocapsid Citations (2)
Originally described in: Targeting the coronavirus nucleocapsid protein through GSK-3 inhibition.Liu X, Verma A, Garcia G Jr, Ramage H, Lucas A, Myers RL, Michaelson JJ, Coryell W, Kumar A, Charney AW, Kazanietz MG, Rader DJ, Ritchie MD, Berrettini WH, Schultz DC, Cherry S, Damoiseaux R, Arumugaswami V, Klein PS Proc Natl Acad Sci U S A. 2021 Oct 19;118(42). pii: 2113401118. doi: 10.1073/pnas.2113401118. Epub 2021 Sep 30. PubMed Journal
Articles Citing SARS-CoV2 Nucleocapsid
| Articles |
|---|
| Interferon-Lambda Intranasal Protection and Differential Sex Pathology in a Murine Model of SARS-CoV-2 Infection. Sohn SY, Hearing J, Mugavero J, Kirillov V, Gorbunova E, Helminiak L, Mishra S, Mackow E, Hearing P, Reich NC, Kim HK. mBio. 2021 Dec 21;12(6):e0275621. doi: 10.1128/mBio.02756-21. Epub 2021 Nov 2. PubMed |
| Targeted intracellular delivery of Cas13 and Cas9 nucleases using bacterial toxin-based platforms. Tian S, Liu Y, Appleton E, Wang H, Church GM, Dong M. Cell Rep. 2022 Mar 8;38(10):110476. doi: 10.1016/j.celrep.2022.110476. PubMed |
If you have published an article using this material, please email us at [email protected] to have your article added to this page.